|Day Low/High||18.90 / 19.70|
|52 Wk Low/High||4.05 / 27.50|
Whether this market continues to bounce is going to depend a great degree on the FAANG names.
Many stocks are already at support levels and are offering opportunities to start some positions.
Study provided proof of concept for development of SB-913 product candidate currently being evaluated in Phase 1/2 clinical trial
4 stocks on my shopping list for when conditions improve.
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Sangamo Therapeutics Inc . The average 12-month price target for SGMO — averaging the work of 6 analysts — reveals an average price target of $23.50/share.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
Kite, a Gilead Company (Nasdaq:GILD) and Sangamo Therapeutics, Inc.
-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --
Here's what you need to know now for Wednesday, Feb. 14.
It's hard to believe the bounce will continue to run in V-shaped fashion.
It is a very different market environment now which can be very rewarding depending on your style.
If we have a little consolidating action here the buyers will start pushing again.
There are signs of stabilization, but the market is still digesting some very big swings.
The volatility trade that propped up markets is no longer available.
It would be a longer-term positive if the overbought conditions are alleviated.
What drives the trading action are structural issues, not macroeconomic news events or political drama.
There is still a very strong appetite for individual stocks with momentum.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.